María Molina‐Molina

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Toby M. Maher, Tamera J. Corte, Aryeh Fischer et al. · The Lancet Respiratory Medicine · 2019 · 630 citations

Medicine, Clinical Sciences, Pharmacotherapy +6

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis

Richard J. Allen, Beatriz Guillén‐Guío, Justin M. Oldham et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 341 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study

Thomas M Drake, Annemarie B Docherty, Ewen M. Harrison et al. · American Journal of Respiratory and Critical Care Medicine · 2020 · 239 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

The JAK2 pathway is activated in idiopathic pulmonary fibrosis

Javier Milara, Gracia Hernandez, Beatriz Ballester et al. · Respiratory Research · 2018 · 189 citations · Full text

Life Sciences, Pathobiology, Pathology +15